Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1368 ARTÍCULOS , VIENDO DEL 16 AL 30

Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease

Talarico G, Trebbastoni A, Bruno G, de Lena C.

Curr Neuropharmacol. 2019;17(2):176-183. doi: 10.2174/1570159X16666180702144644.

Six-Month Effectiveness of Remote Activity Monitoring for Persons Living With Dementia and Their Family Caregivers: An Experimental Mixed Methods Study

Gaugler JE, Zmora R, Mitchell LL, Finlay JM, Peterson CM, McCarron H, Jutkowitz E.

Gerontologist. 2019 Jan 9;59(1):78-89. doi: 10.1093/geront/gny078.

Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease - A Literature Review

Basavan D, Chalichem NSS, Kumar MKS.

Curr Drug Targets. 2019;20(3):263-291. doi: 10.2174/1389450119666180813095637.

Case Report of a 63-Year-Old Patient With Alzheimer Disease and a Novel Presenilin 2 Mutation

Wells JL, Pasternak SH.

Alzheimer Dis Assoc Disord. 2019 Apr-Jun;33(2):166-169. doi: 10.1097/WAD.0000000000000269.

Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review

Alam J, Sharma L.

Curr Drug Targets. 2019;20(3):316-339. doi: 10.2174/1389450119666180820104723.

Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update

Hoskin JL, Al-Hasan Y, Sabbagh MN.

Nicotine Tob Res. 2019 Feb 18;21(3):370-376. doi: 10.1093/ntr/nty116.

Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update

Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, Ashraf GM, Ahmad M.

Curr Neuropharmacol. 2019;17(3):232-246. doi: 10.2174/1570159X16666180828100002.

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Cardoso BR, Roberts BR, Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ, Hare DJ, Bush AI.

Neurotherapeutics. 2019 Jan;16(1):192-202. doi: 10.1007/s13311-018-0662-z.

Alzheimer's Disease - Future Therapy Based on Dendrimers

Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutovа A, Baeesa SS, Avila-Rodriguez M, Ustyugov AA, Bachurin SO.

Curr Neuropharmacol. 2019;17(3):288-294. doi: 10.2174/1570159X16666180918164623.

Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?

Zholos AV, Moroz OF, Storozhuk MV.

Curr Mol Pharmacol. 2019;12(1):12-26. doi: 10.2174/1874467211666181012150847.

Alzheimer Dementia in the Orthopaedic Patient

Aneja A, Zuelzer DA, Moghadamian ES, Kates SL.

J Am Acad Orthop Surg. 2019 Apr 1;27(7):e311-e318. doi: 10.5435/JAAOS-D-17-00661.

A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach

Rabiee N, Bagherzadeh M, Rabiee M.

Curr Diabetes Rev. 2019;15(4):255-258. doi: 10.2174/1573399814666181031154817.

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial

Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, Marcal T, Solomon E, Boumis A, Bet A, Mennes M, van Oort E, Beckmann CF, Braithwaite SP, Jackson S, Nikolich K, Stephens D, Kerchner GA, Wyss-Coray T.

JAMA Neurol. 2019 Jan 1;76(1):35-40. doi: 10.1001/jamaneurol.2018.3288.

Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets

Gupta S, Singhal NK, Ganesh S, Sandhir R.

CNS Neurol Disord Drug Targets. 2019;18(3):172-184. doi: 10.2174/1871527317666181114163515.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias